Inhibition of lncRNA NEAT1 sensitizes medulloblastoma cells to cisplatin through modulating the miR-23a-3p-glutaminase (GLS) axis

References

• Northcott PA, Robinson GW, Kratz CP, et al. Medulloblastoma. Nat Rev Dis Primers. 2019;5(1):11.
   PubMed Web of Science ®Google Scholar
• Thompson EM, Bramall A, Herndon JE, et al. The clinical importance of medulloblastoma extent of resection: a systematic review. J Neurooncol. 2018;139:523–539.
   PubMed Web of Science ®Google Scholar
• Archer TC, Mahoney EL, Pomeroy SL. Medulloblastoma: molecular classification-based personal therapeutics. Neurotherapeutics. 2017;14:265–273.
   PubMed Web of Science ®Google Scholar
• Wang J, Garancher A, Ramaswamy V, et al. Medulloblastoma: from molecular subgroups to molecular targeted therapies. Annu Rev Neurosci. 2018;41:207–232.
   PubMed Web of Science ®Google Scholar
• Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;740:364–378.
   PubMed Web of Science ®Google Scholar
• Ghosh S. Cisplatin: the first metal based anticancer drug. Bioorg Chem. 2019;88:102925.
   PubMed Web of Science ®Google Scholar
• Amable L. Cisplatin resistance and opportunities for precision medicine. Pharmacol Res. 2016;106:27–36.
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Senovilla L, Vitale I, et al. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31:1869–1883.
   PubMed Web of Science ®Google Scholar
• Ghafouri-Fard S, Shoorei H, Taheri M. The role of long non-coding RNAs in cancer metabolism: a concise review. Front Oncol. 2020;10:555825.
   PubMed Web of Science ®Google Scholar
• Huarte M. The emerging role of lncRNAs in cancer. Nat Med. 2015;21(11):1253–1261.
   PubMed Web of Science ®Google Scholar
• Yu X, Li Z, Zheng H, et al. NEAT1: a novel cancer-related long non-coding RNA. Cell Prolif. 2017;50:e12329.
   PubMed Web of Science ®Google Scholar
• Li T, Le A. Glutamine metabolism in cancer. Adv Exp Med Biol. 2018;1063:13–32.
   PubMed Web of Science ®Google Scholar
• Yang L, Venneti S, Nagrath D. Glutaminolysis: a Hallmark of cancer metabolism. Annu Rev Biomed Eng. 2017;19:163–194.
   PubMed Web of Science ®Google Scholar
• Luengo A, Gui DY, Vander Heiden MG. Targeting metabolism for cancer therapy. Cell Chem Biol. 2017;24:1161–1180.
   PubMed Web of Science ®Google Scholar
• Niklison-Chirou MV. Glutamine metabolism, the Achilles heel for medulloblastoma tumor. Cell Death Dis. 2018;9:74.
   PubMed Web of Science ®Google Scholar
• Li JH, Liu S, Zhou H, et al. starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res. 2014;42:D92–97.
   PubMed Web of Science ®Google Scholar
• Hawkins SFC, Guest PC. Multiplex analyses using real-time quantitative PCR. Methods Mol Biol. 2017;1546:125–133.
   PubMedGoogle Scholar
• Paraskevopoulou MD, Hatzigeorgiou AG. Analyzing MiRNA-LncRNA interactions. Methods Mol Biol. 2016;1402:271–286.
   PubMedGoogle Scholar
• Iorio MV, Croce CM. MicroRNA dysregulation in cancer: diagnostics, monitoring and therapeutics. A comprehensive review. EMBO Mol Med. 2012;4:143–159.
   PubMed Web of Science ®Google Scholar
• Nie JH, Li TX, Zhang XQ, et al. Roles of non-coding RNAs in normal human brain development, brain tumor, and neuropsychiatric disorders. Noncoding RNA. 2019;5:36.
   PubMed Web of Science ®Google Scholar
• Chen MY, Fan K, Zhao LJ, et al. Long non-coding RNA nuclear enriched abundant transcript 1 (NEAT1) sponges microRNA-124-3p to up-regulate phosphodiesterase 4B (PDE4B) to accelerate the progression of Parkinson’s disease. Bioengineered. 2021;12:708–719.
   PubMed Web of Science ®Google Scholar
• An Q, Zhou Z, Xie Y, et al. Knockdown of long non-coding RNA NEAT1 relieves the inflammatory response of spinal cord injury through targeting miR-211-5p/MAPK1 axis. Bioengineered. 2021;12:2702–2712.
   PubMed Web of Science ®Google Scholar
• Chen J, Zhang Y, Tan W, et al. Silencing of long non-coding RNA NEAT1 improves Treg/Th17 imbalance in preeclampsia via the miR-485-5p/AIM2 axis. Bioengineered. 2021;12:8768–8777.
   PubMed Web of Science ®Google Scholar
• Yang C, Li Z, Li Y, et al. Long non-coding RNA NEAT1 overexpression is associated with poor prognosis in cancer patients: a systematic review and meta-analysis. Oncotarget. 2017;8:2672–2680.
   PubMedGoogle Scholar
• Ma M, Dai J, Tang H, et al. MicroRNA-23a-3p inhibits mucosal melanoma growth and progression through targeting adenylate cyclase 1 and attenuating cAMP and MAPK pathways. Theranostics. 2019;9:945–960.
   PubMed Web of Science ®Google Scholar
• Chen F, Qi S, Zhang X, et al. miR-23a-3p suppresses cell proliferation in oral squamous cell carcinomas by targeting FGF2 and correlates with a better prognosis: miR-23a-3p inhibits OSCC growth by targeting FGF2. Pathol Res Pract. 2019;215:660–667.
   PubMed Web of Science ®Google Scholar
• Ding F, Lai J, Gao Y, et al. NEAT1/miR-23a-3p/KLF3: a novel regulatory axis in melanoma cancer progression. Cancer Cell Int. 2019;19:217.
   PubMed Web of Science ®Google Scholar
• Wang H, Xue W, Ouyang W, et al. miR-23a-3p/SIX1 regulates glucose uptake and proliferation through GLUT3 in head and neck squamous cell carcinomas. J Cancer. 2020;11:2529–2539.
   PubMed Web of Science ®Google Scholar
• Gao P, Tchernyshyov I, Chang TC, et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature. 2009;458:762–765.
   PubMed Web of Science ®Google Scholar
• Zhu L, WangF, Fan W, et al. lncRNA NEAT1 promotes the taxol resistance of breast cancer via sponging the miR-23a-3p-FOXA1 axis. Acta Biochim Biophys Sin (Shanghai). 2021;53:1198–1206.
   PubMed Web of Science ®Google Scholar
• Rao Y, Fang Y, Tan W, et al. Delivery of long non-coding RNA NEAT1 by peripheral blood mononuclear cells-derived exosomes promotes the occurrence of rheumatoid arthritis via the MicroRNA-23a/MDM2/SIRT6 axis. Front Cell Dev Biol. 2020;8:551681.
   PubMed Web of Science ®Google Scholar
• Ding F, Lai J, Gao Y, et al. NEAT1/miR-23a-3p/KLF3: a novel regulatory axis in melanoma cancer progression. Cancer Cell Int. 2019;19:217.
   PubMed Web of Science ®Google Scholar
• Zhao C, Wang S, Zhao Y, et al. Long noncoding RNA NEAT1 modulates cell proliferation and apoptosis by regulating miR-23a-3p/SMC1A in acute myeloid leukemia. J Cell Physiol. 2019;234:6161–6172.
   PubMed Web of Science ®Google Scholar
• Vaupel P, Schmidberger H, Mayer A. The Warburg effect: essential part of metabolic reprogramming and central contributor to cancer progression. Int J Radiat Biol. 2019;95:912–919.
   PubMed Web of Science ®Google Scholar
• Cocetta V, Ragazzi E, Montopoli M. Links between cancer metabolism and cisplatin resistance. Int Rev Cell Mol Biol. 2020;354:107–164.
   PubMed Web of Science ®Google Scholar
• Guo J, Satoh K, Tabata S, et al. Reprogramming of glutamine metabolism via glutamine synthetase silencing induces cisplatin resistance in A2780 ovarian cancer cells. BMC Cancer. 2021;21:174.
   PubMed Web of Science ®Google Scholar